Bioequivalence and safety of a novel fentanyl transdermal matrix system compared with a transdermal reservoir system

Journal of Opioid Management

Volumn 7, Issue 2, 2011, Pages 99-107

  Moore, Kenneth Todd ^a   Adams, Holly D ^a   Natarajan, Jaya ^a   Ariyawansa, Jay ^a   Richards, Henry M ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Drug delivery; Fentanyl; Matrix; Pharmacokinetics; Transdermal

Indexed keywords

FENTANYL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD; CHRONIC PAIN; CONFIDENCE INTERVAL; CROSSOVER PROCEDURE; FEMALE; GEOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANALGESICS, OPIOID; CROSS-OVER STUDIES; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 79955937048     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0052     Document Type: Article

References (23)

1. Muijsers RB, Wagstaff AJ: Transdermal fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001; 61(15): 2289-2307. (Pubitemid 34074808)
2. Grond S, Radbruch L, Lehmann KA: Clinical pharmacokinetics of transdermal opioids: Focus on transdermal fentanyl. Clin Pharmacokinet. 2000; 38(1): 59-89. (Pubitemid 30055094)
3. Varvel JR, Shafer SL, Hwang SS, et al.: Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989; 70(6): 928-934. (Pubitemid 19148495)
4. Mather LE: Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983; 8(5): 422-446.
5. McClain DA, Hug CC Jr: Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980; 28(1): 106-114. (Pubitemid 10090693)
6. Peng PW, Sandler AN: A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology. 1999; 90(2): 576-599. (Pubitemid 29071528)
7. Hug CC Jr, Murphy MR: Tissue redistribution of fentanyl and termination of its effects in rats. Anesthesiology. 1981; 55(4): 369-375.
8. Meuldermans WE, Hurkmans RM, Heykants JJ: Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int de Pharmacodyn Ther. 1982; 257(1): 4-19. (Pubitemid 12071181)
9. Goromaru T, Matsuura H, Yoshimura N, et al.: Identification and quantitative determination of fentanyl metabolites in patients by gas chromatographyÑMass spectrometry. Anesthesiology. 1984; 61(1): 73-77. (Pubitemid 14089358)
10. Labroo RB, Paine MF, Thummel KE, et al.: Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos. 1997; 25(9): 1072-1080. (Pubitemid 27396495)
11. Andrews CJH, Prys-Roberts C: Fentanyl: A review. Clin Anesthesiol. 1983; KD: 97-122.
12. Lilleng PK, Mehlum LI, Bachs L, et al.: Deaths after intravenous misuse of transdermal fentanyl. J Forensic Sci. 2004; 49(6): 1364-1366. (Pubitemid 39453200)
13. Kuhlman JJ Jr, McCaulley R, Valouch TJ, et al.: Fentanyl use, misuse, and abuse: A summary of 23 postmortem cases. J Anal Toxicol. 2003; 27(7): 499-504. (Pubitemid 37185862)
14. Arvanitis ML, Satonik RC: Transdermal fentanyl abuse and misuse. Am J Emerg Med. 2002; 20(1): 58-59.
15. Reeves MD, Ginifer CJ: Fatal intravenous misuse of transdermal fentanyl. Med J Aust. 2002; 177(10): 552-553. (Pubitemid 35422818)
16. Marquardt KA, Tharratt RS, Musallam NA: Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother. 1995; 29(10): 969-971.
17. Phipps B, Cormier M, Gale B, et al.: Transdermal drug delivery. In Wnek GE, Bowlin GL (eds.): Encyclopedia of Biomaterials and Biomedical Engineering. 2nd ed. New York: Marcel Dekker, Inc., 2008: 2893-2905.
18. Sathyan G, Guo C, Sivakumar K, et al.: Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin. 2005; 21(12): 1961-1968. (Pubitemid 41803107)
19. Lehmann KA, Zech D: Transdermal fentanyl: Clinical pharmacology. J Pain Symptom Manage. 1992; 7(3 Suppl): S8-S16.
20. Marier JF, Lor M, Potvin D, et al.: Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol. 2006; 46(6): 642-653.
21. Marier JF, Lor M, Morin J, et al.: Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation. Br J Clin Pharmacol. 2007; 63(1): 121-124. (Pubitemid 44902886)
22. Miyazaki T, Hanaoka K, Namiki A, et al.: Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. Clin Drug Investig. 2008; 28(5): 313-325. (Pubitemid 351521384)
23. Kress HG, Boss H, Delvin T, et al.: Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent. Eur J Pharm Biopharm. 2010; 75(2): 225-231.